TGTX Projected Dividend Yield
TG Therapeutics Inc ( NASDAQ : TGTX )TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. Co. is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. 21 YEAR PERFORMANCE RESULTS |
TGTX Dividend History Detail TGTX Dividend News TGTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |